303136-12-1

Basic information

• Product Name: 4-nitro-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide
• Synonyms: 4-nitro-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide
• CAS NO: 303136-12-1
• Molecular Formula: C₁₂H₁₇N₃O₅S
• Molecular Weight: 315.34548
• Mol File: 303136-12-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-nitro-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-nitro-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide(303136-12-1)
• EPA Substance Registry System: 4-nitro-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide(303136-12-1)

Safety Data

• Hazardous Substances Data: 303136-12-1(Hazardous Substances Data)

Upstream product

• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 1784-16-3 4-amino-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide 
• 1306720-98-8 N-[4-(2-morpholin-4-yl-ethylsulfamoyl)-phenyl]-acrylamide 

Relevant articles and documents

TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase

The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N′-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS

Disclosed are sulfonamide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases.